Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Catalyst Biosciences Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Catalyst Biosciences Inc market cap is $1.46B.
What is the 52-week high for Catalyst Biosciences Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Catalyst Biosciences Inc 52 week high is $30.40 as of September 15, 2025.
What is the 52-week low for Catalyst Biosciences Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Catalyst Biosciences Inc 52 week low is $3.00 as of September 15, 2025.
What is Catalyst Biosciences Inc stock price today?
Catalyst Biosciences Inc stock price today is $16.42.
What was Catalyst Biosciences Inc stock price yesterday?
Catalyst Biosciences Inc stock price yesterday was $17.11.
What is the PE ratio of Catalyst Biosciences Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Catalyst Biosciences Inc’s P/E ratio is -0.97.
What is the Price-to-Book ratio of Catalyst Biosciences Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Catalyst Biosciences Inc P/B ratio is -1.4541.
What is Catalyst Biosciences Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Catalyst Biosciences Inc's EBITDA is -3.35.
What is the 50-day moving average of Catalyst Biosciences Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Catalyst Biosciences Inc 50-day moving average is $17.62.
